中医药治疗 COVID-19 的直接证据和机制。
The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.
机构信息
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China; China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China; Beijing University of Chinese Medicine, Beijing, 100029, China.
出版信息
Biomed Pharmacother. 2021 May;137:111267. doi: 10.1016/j.biopha.2021.111267. Epub 2021 Jan 14.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus causing serious human disease to spread across the world in the past 20 years, after SARS and Middle East respiratory syndrome. As of mid-September 2020, more than 200 countries and territories have reported 30 million cases of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, including 950,000 deaths. Supportive treatment remains the mainstay of therapy for COVID-19. The World Health Organization reported that four candidate drugs, including remdesivir, are ineffective or have little effect on COVID-19. According to China News, 90 % of Chinese patients with COVID-19 use traditional Chinese medicine (TCM), with an effectiveness rate of 80 %, and no deterioration in patient condition. We have compiled the direct evidence of TCM treatment for COVID-19 as of December 31, 2020. We describe the advantages of TCM in the treatment of COVID-19 based on clinical evidence and the required methods for its clinical use. TCM can inhibit virus replication and transcription, prevent the combination of SARS-CoV-2 and the host, and attenuate the cytokine storm and immune deficiency caused by the virus infection. The cooperation of many countries is required to establish international guidelines regarding the use of TCM in patients with severe COVID-19 from other regions and of different ethnicities. Studies on the psychological abnormalities in patients with COVID-19, and medical staff, is lacking; it is necessary to provide a complete chain of evidence to determine the efficacy of TCM in the related prevention, treatment, and recovery. This study aims to provide a reference for the rational use of TCM in the treatment of COVID-19.
严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)是过去 20 年来第三种在全球传播的导致严重人类疾病的冠状病毒,前两种分别是 SARS 和中东呼吸综合征。截至 2020 年 9 月中旬,已有 200 多个国家和地区报告了由 SARS-CoV-2 引起的 3000 万例 2019 年冠状病毒病(COVID-19)病例,其中包括 95 万人死亡。支持性治疗仍然是 COVID-19 治疗的主要方法。世界卫生组织报告称,包括瑞德西韦在内的四种候选药物对 COVID-19 无效或效果甚微。据《中国新闻》报道,90%的中国 COVID-19 患者使用中药(TCM),有效率为 80%,且患者病情无恶化。我们截至 2020 年 12 月 31 日汇编了 TCM 治疗 COVID-19 的直接证据。我们根据临床证据和 TCM 临床应用所需的方法描述了 TCM 在 COVID-19 治疗中的优势。TCM 可以抑制病毒复制和转录,阻止 SARS-CoV-2 与宿主结合,并减轻病毒感染引起的细胞因子风暴和免疫缺陷。需要许多国家合作,为来自不同地区和不同种族的重症 COVID-19 患者制定使用 TCM 的国际指南。目前缺乏针对 COVID-19 患者和医务人员心理异常的研究;有必要提供完整的证据链,以确定 TCM 在相关预防、治疗和康复中的疗效。本研究旨在为 TCM 在 COVID-19 治疗中的合理应用提供参考。
相似文献
Biomed Pharmacother. 2021-5
Chin J Nat Med. 2020-12
引用本文的文献
J Public Health Afr. 2025-4-18
Biosaf Health. 2023-9-9
World J Otorhinolaryngol Head Neck Surg. 2024-5-30
Chin J Integr Med. 2024-11
Biochem Biophys Rep. 2023-12-26
本文引用的文献
Natl Sci Rev. 2020-6
MMWR Morb Mortal Wkly Rep. 2021-1-1
Biomed Pharmacother. 2020-11-19
ACS Nano. 2020-10-9
Nan Fang Yi Ke Da Xue Xue Bao. 2020-9-30
Clin Exp Immunol. 2020-10-12